|
| Reference/year | Age/Sex | Location | Size (cm) | Folpe cat. | Management | Outcome | Treatment details |
|
| Neoadjuvant cases | | | | | | | |
|
Folpe et al. [7] | 49 F | Shoulder | N/A | Malignant | NA CT, resection | NED at 11 mo | Ifos/Adria—residual dz at resection |
|
Jeon and Sung [34] and Jeon and Yi [35] | 9 F | Uterus | 6.5 | Malignant | NA CT, resection, Adj CT | NED at 16 mo; ALL diagnosed at 16 mo | Vincr/Ifos/Adria—2 NA cycles, 6 adj cycles concurrent with 45 Gy. |
| Ong et al. [36] | 8 F | Vagina | 2 | Unknown | NA CT, resection | NED at 6 mo | Ifos/Vincr/Actino D x3—prog |
| Osei et al. [37] | 49 F | UE soft tissue | 5.3 | Malignant | Sequential NA CT then RT followed by resection | Single lung metastasis at 14 mo—resected | Ifos/Adria x6—80% reduction, then 50 Gy RT—prog |
| Weinreb et al. [38] | 68 M | Thigh | 7.8 | Malignant | NA RT, resection | NED at 11 mo | |
| Yamashita et al. [39] | 39 F | Tibia | 6.5 | Malignant | NA RT, resection | NED at 34 mo | |
|
| Adjuvant Cases | | | | | | | |
| Bosincu et al. [40] | 48 F | Uterus | 7 | Malignant | Resection, Adj HT | NED at 36 mo | Tamoxifen |
| Chen et al. [41] | 16 F | Abdominal | 27 | Malignant | Resection, Adj CT | Recurrence at 2 mo; no further follow-up | (+) LN at surgery |
| Fink et al. [42] | 51 F | Broad Lig | 17 | Unknown | Resection, Adj RT | NED at 15 mo | 50.4 Gy |
| Folpe et al. [43] | 29 M | Falciform Lig | 20 | Malignant | Resection, Adj RT | Lung metastases at 3 mo; dead of other causes at 1 yr | |
| Folpe et al. [43] | 10 F | Falciform Lig | 5 | Unknown | Resection, Adj CT | Lost to follow-up | Vincr, Actino D, Cyclophos |
| Folpe et al. [7] | 71 M | Forearm | 9 | Malignant | Resection, Adj RT | NED at 10 mo | |
| Folpe et al. [7] | 48 F | Cervix | 2 | Unknown | Resection, Adj RT | NED at 21 mo | |
| Folpe et al. [7] | 77 F | Neck | 2.6 | Unknown | Resection, Adj RT | NED at 6 mo | |
| Folpe et al. [7] | 56 F | Uterus | 9 | Malignant | Resection, Adj CT and RT | Lung and bony metastases at 11 mo; alive at 11 mo | |
| Folpe et al. [7] | 59 F | Uterus | 14.5 | Malignant | Resection, Adj CT | Liver and lung metastases at 30 mo; alive at 30 mo | |
| Folpe et al. [7] | 46 F | Mesentery | 12 | Malignant | Resection, Adj CT | Intra-abdominal and liver metastases at 22 mo; DOD at 27 mo | “Multiple” cycles of adjuvant CT |
| Folpe et al. [7] | 36 F | Uterus | N/A | Malignant | Resection, Adj CT | Lung metastases at 12 mo, liver metastases at 36 mo; DOD at 39 mo | |
| Hornick and Fletcher [11] | 50 F | Pelvis | 13 | Malignant | Resection, Adj RT | Lung, liver, abdominal wall metastases at 39 mo, alive at 46 mo | |
| Pan et al. [20] | 46 M | Prostate | 8.5 | Malignant | Resection, Adj RT | Pulmonary metasases at 3 yrs, DOD at 4 yrs | Cis/Adria x6 cycles |
| Parfitt et al. [44] | 48 M | Bladder | 3 | Unknown | Resection, Adj IT | NED at 48 mo | IFN-α |
| Ryan et al. [45] | 15 F | Rectum | 3.7 | Malignant | Resection, Adj CT | NED at 9 mo | (+) LN at surgery; Ifos/Adria |
| Silva et al. [4] | 76 F | Uterus | N/A | Malignant | Resection, Adj RT | NED at 8 mo | |
| Subbiah et al. [46] | 58 F | Retroperitoneal | 17 | Unknown | Resection, Adj CT | Liver metastases at 2 yrs, resected with subsequent liver and lung metastases | 2 cycles adj Adria; RT/adria after resection of liver recurrence; temsirolimus/bortezomib at 2nd recurrence—prog |
| Vang and Kempson [47] | 75 F | Uterus | 5 | Unknown | Resection, Adj RT | NED at 30 mo | |
|
| Metastatic/Recurrent Cases | | | | | | | |
| Bonetti et al. [48] | 19 F | Uterus | 5.5 | Malignant | Subtotal resection of primary, CT followed by RT | Local recurrence at 10 mo, diffuse metastatic disease at 18 mo | |
|
Léon et al. [49] | 76 F | Abdominal | 15 | Malignant | RT to sacral recurrence | Progressive metastatic disease | 13 Gy RT to sacrum |
|
Léon et al. [49] | 38 F | Retroperitoneal | N/A | Malignant | CRT | DOD at 20 mo | RT/Thal |
| Fukunaga et al. [50] | 40 F | Uterus | 30 | Malignant | Debulking surgery, CRT | DOD at 17 mo | Mulitple omental metastases at initial surgery |
| Greene et al. [51] | 79 F | Uterus | 13 | Malignant | Debulking of pelvic recurrence, CT | DOD at “several” mo | Paclitaxel x1 cycle |
| Italiano et al. [52] | 55 F | Uterus | N/A | Unknown | Resection of recurrence, CT, CRT following 2nd recurrence, mTOR following progression | Progressive metastatic disease; alive at 16 mo following recurrence | Ifos/Adria, RT+etop, Temsirolimus, Gem |
| Italiano et al. [52] | 69 F | Uterus | N/A | Unknown | mTOR, resection of solitary lung metastasis | NED at 9 mo | Temsirolimus; response allowed surgical resection |
| Peng et al. [53] | 47 M | Pelvis | 12 | Malignant | Subtotal resection of primary, CT | DOD at 9 mo | Ifos/Epi x2—prog; Adria/Oxali/Thal x 2—prog; Nada, Dacarb x2—prog |
| Silva et al. [4] | 47 F | Uterus | N/A | Malignant | Resection of primary; RT followed by CT | DOD at 30 mo | Lung metastases at diagnosis; Adria/Cis x8 cycles |
| Silva et al. [4] | 73 F | Uterus | N/A | Malignant | Resection of primary; CT | DOD at 9 mo | Paclitaxel x6 cycles |
| Silva et al. [4] | 43 F | Uterus | N/A | Malignant | Resection of primary; CT | Alive with progressive disease at 6 mo | Ifos/Adria x5 cycles |
| Wagner et al. [54] | 70 M | Kidney | 9 | Unknown | TKI, mTOR inhibitor, resection of recurrence | 40% reduction in size of isolated recurrence, NED after resection | Sunitinib, sirolimus |
| Wagner et al. [54] | 65 M | Retroperitoneal | 20 | Malignant | Resection of recurrences, mTOR inhibitor | “Near complete dissapperance” of multifocal disease at 12 mo, alive at 16 mo following recurrence | Sirolimus |
| Wagner et al. [54] | 61 F | Cervix | 9 | Malignant | mTOR inhibitor | Initial response, DOD at 8 mo | Sirolimus |
| Yamashita et al. [39] | 35 M | Vertebral | 1.8 | Malignant | CRT | Bone metastases at 9 mo, alive at 12 mo | Pelvic mets—no tx details |
| Yamashita et al. [39] | 42 F | Uterus | 15 | Malignant | Resection of humeral recurrence, CT | DOD at 10 mo with diffuse metastases | |
|
